Abstract
A proliferation-inducing ligand (APRIL) of the tumour necrosis factor (TNF) family is produced in small amounts in many tissues and more abundantly in tumours. APRIL has been reported to promote cell growth in vivo and in vitro. It was recently shown that the production of APRIL in some glioblastoma cell lines does not lead to an increase in cell growth. In this study, we investigated the production of APRIL and its ability to increase the proliferation of eight human glioblastoma cell lines. We found that APRIL was produced in the eight human glioblastoma cell lines tested but not in the normal embryonic astrocyte counterparts of glioblastomas. Flow cytometry demonstrated the presence of a specific APRIL-binding receptor on the cell surface in all the glioblastoma cell lines tested. This receptor was also present on normal embryonic and adult astrocytes and embryonic neural progenitor cells. Moreover, the addition of recombinant human APRIL resulted in an increase in proliferation rate of normal adult astrocytes and in four of eight cell lines tested. Addition of the soluble recombinant TNF-receptor-homologue B-cell maturation (BCMA) chimeric protein, which binds APRIL, confirmed the involvement of APRIL in the growth of malignant glioblastoma cell lines.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Barbero S, Bonavia R, Bajetto R, Porcile C, Pirani P, Ravetti JL, Zona GL, Spaziante R, Florio T and Schettini G . (2003). Cancer Res., 63, 1969–1974.
Chamak B and Prochiantz A . (1989). Development, 106, 483–491.
Davies LG, Dibner MD and Batley JF . (1986). Basic Methods in Molecular Biology. Elsevier: New York.
Goswami S, Gupta A and Sharma SK . (1998). J. Neurochem., 71, 1837–1845.
Gravestein LA and Borst J . (1998). Sem. Immunol., 10, 423–434.
Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, Moore M, Littau A, Grossman A, Haugen H, Foley K, Blumberg H, Harrison K, Kindsvogel W and Clegg CH . (2000). Nature, 404, 995–999.
Hahne M, Kataoka T, Schröter M, Hofmann K, Irmler M, Bodmer J-L, Schneider P, Bornand T, Holler N, French LE, Sordat B, Rimoldi D and Tschopp J . (1998). J. Exp. Med., 188, 1185–1190.
Hansen MB, Nielsen SE and Berg K . (1989). J. Immunol. Methods, 119, 203–210.
Held-Feindt J, Lutjohann B, Ungefroren H, Mehdorn HM and Mentlein R . (2003). J. Neurooncol., 63, 117–127.
Kelly K, Manos E, Jensen G, Nadauld L and Jones DA . (2000). Cancer Res., 60, 1021–1027.
Laâbi Y, Gras MP, Brouet JC, Berger R, Larsen CJ and Tsapis A . (1994). Nucleic Acids Res., 22, 1147–1154.
Laâbi Y, Gras MP, Carbonel F, Brouet JC, Berger R, Larsen CJ and Tsapis A . (1992). EMBO J., 11, 3897–3904.
López-Fraga M, Fernández R, Albar JP and Hahne M . (2001). EMBO Rep., 21, 945–951.
Madry C, Laâbi Y, Callebaut I, Roussel J, Hatzoglou A, Le Coniat M, Mornon JP, Berger R and Tsapis A . (1998). Int. Immunol., 10, 1693–1702.
Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM and Ashkenazi A . (2000). Curr. Biol., 10, 785–788.
Miloux B and Lupker JH . (1994). Gene, 149, 341–344.
Rennert P, Schneider P, Cachero TG, Thompson J, Trabach L, Hertig S, Holler N, Qian F, Mullen C, Strauch K, Browning JL, Ambrose C and Tschopp J . (2000). J. Exp. Med., 192, 1677–1683.
Ridet J-L, Corti O, Pencalet P, Mahanoun N, Hamon M, Philippon J and Mallet J . (1999). Human Gene Ther., 10, 271–280.
Roth W, Wagenknecht B, Klumpp A, Naumann U, Hahne M, Tschopp J and Weller M . (2001). Cell Death Differ., 8, 403–410.
Schneider P, MacKay F, Steiner V, Hoofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL and Tschopp J . (1999). J. Exp. Med., 189, 1747–1756.
Shu HB, Hu WH and Johnson H . (1999). J. Leuk. Biol., 65, 680–683.
Smith CA, Farrah T and Goodwin RG . (1994). Cell, 76, 959–962.
Thompson JS, Bixler SA, Qian F, Vora K, Scott MA, Cachero TG, Hession C, Schneider P, Sizing ID, Mullen C, Strauch K, Zafari M, Benjamin CD, Tschopp J, Browning JL and Ambrose C . (2001). Science, 293, 2108–2111.
Thompson JS, Schneider P, Kalled SL, Wang LC, Lefevre EA, Cachero TG, MacKay F, Bixler SA, Zafari M, Liu ZY, Woodcock SA, Qiang F, Batten M, Madry C, Richard Y, Benjamin CD, Browning JL, Tsapis A, Tschopp J and Ambrose C . (2000). J. Exp. Med., 192, 129–135.
Wu Y, Bressette D, Carrell JA, Kaufman T, Feng P, Taylor K, Gan Y, Cho YH, Garcia AD, Gollatz E, Dimke D, La Fleur D, Migone TS, Nardelli B, Wei P, Ruben SM, Ullrich SJ, Olsen HS, Kanakaraj P, Moore PA and Baker KP . (2000). J. Biol. Chem., 275, 35478–35485.
Xia XZ, Treanor J, Senaldi G, Khare SD, Boone T, Kelley M, Theill LE, Colombero A, Solovnev I, Lee F, McCabe S, Elliott R, Miner K, Hawkins N, Guo J, Stolina M, Yu G, Wang J, Delaney J, Meng SY, Boyle WJ and Hsu H . (2000). J. Exp. Med., 192, 137–144.
Yu G, Boone T, Delaney J, Hawkins N, Kelley M, Ramakrishnan M, McCabe S, Qiu WR, Kornuc M, Xia XZ, Guo J, Stolina M, Boyle WJ, Sarosi I, Hsu H, Senaldi G and Theill LE . (2000). Nat. Immunol., 1, 252–256.
Acknowledgements
We thank Dr Gabriel GRAS (CEA, Fontenay aux Roses, France) and Dr Delpech (Centre H Becquerel, CHU de Rouen, France) for generously providing glioblastoma cell lines and Drs Brigitte Miloux and Jan Lupker (Sanofi Recherche, Labège, France) for generously providing p7055. This work was supported by INSERM (Institut National de la Santé et de la Recherche Médicale) and by ARC (Association de la Recherche contre le Cancer, grant 4204).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Deshayes, F., Laprée, G., Portier, A. et al. Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor. Oncogene 23, 3005–3012 (2004). https://doi.org/10.1038/sj.onc.1207350
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207350
Keywords
This article is cited by
-
Involvement of APRIL in Helicobacter pylori-related gastric cancer
Journal of Cancer Research and Clinical Oncology (2021)
-
TNFSF13 upregulation confers chemotherapeutic resistance via triggering autophagy initiation in triple-negative breast cancer
Journal of Molecular Medicine (2020)
-
APRIL and BAFF: novel biomarkers for central nervous system lymphoma
Journal of Hematology & Oncology (2019)
-
Expression profile analysis of antisense long non-coding RNA identifies WDFY3-AS2 as a prognostic biomarker in diffuse glioma
Cancer Cell International (2018)
-
Tumor necrosis factor superfamily member APRIL contributes to fibrotic scar formation after spinal cord injury
Journal of Neuroinflammation (2016)